We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments. Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go: Expired investment: Withheld
Projekt Rising (PR) is an automated project management Software as a Service (SaaS) portal that delivers projects to clients by replacing freelance teams and project managers with intelligent automation. The platform provides services such as video production, web and print content, and e-learning projects. It asserts that its model in the interactive and pharmaceutical industries has led to delivery times being cut in half, costs reduced by >50%, with the highest industry quality standards being maintained throughout. PR aims to be a contender in the £57 billion Project Management Professional (PMP) market. It will use the investment to grow its business across different verticals.
days to go: Expired investment: £51,060
ITIG have developed software to aid in understanding the investment process, as well as reducing the associated costs of investing. Using their licensed methodologies, retail and institutional investors will see return funds which are more predictable when investing in Exchange Traded Funds (ETFs), resulting in highly diverse and low-cost investment portfolio.
days to go: Expired investment: £67,000
Metal matrix composite components and materials, primarily comprised of aluminium for use in the engineering and manufacturing industries. Alvant specialise in designing, developing and producing the composite for well-known clients such as Ford and Safran. In the last financial year, Alvant achieved a turnover of almost £617k and has invested more than £10m towards manufacturing and testing their own product. Alvant is now raising funds to distribute their components to a wider market and expand the number of commercial applications that would benefit from their materials.
days to go: Expired investment: £2,105,001
CareGREEN is an innovation company that has created a unique air pollution capture and storage technology with the aim to reduce harmful pollution in the atmosphere. Their latest product is the Environmental Air Purification Intervention & Control System (EAPICS). The technology has been accredited as a significant solution in reducing COx worldwide. A World Health Organisation (2016) report established that more than 80% of people living in urban areas face the greatest environmental risk to their health today due to air pollution. CareGREEN believes its specialised filtration systems will contribute to a considerable fall in health issues linked to poor air quality. It is also diversifying its reach in other renewable energy sectors such as solar and wind. The company will utilise the investment to scale its business.
days to go: Expired investment: Withheld
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go: Expired investment: £65,004
Trustco Capital is a value-added financial intermediary that acts as a bridge between suppliers and users of capital. Through its investor network, the company supports entrepreneurs and startup enterprises with capital allowing their business to advance further. The company's partnership venture, ‘The Envestry Investment Management Programme’, allows Trustco, as a licensee, the ability to introduce its investor client network and its deals to Envestors and the other licensees leading to a combined investor network of over 6,000+ individuals. This also allows users to view 20 to 30 deals that are mostly SEIS and EIS eligible backed by the Financial Conduct Authority (FCA). 

Pitch Rated

38%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Tom & Teddy Limited is a family-centric global swimwear brand started by Bristol-based female-founder. Tom & Teddy is a beachwear brand for men & boys that has sold more than 55,000 shorts in 2018 generating a revenue of approximately US$1.8m. The shorts are made in a quick-dry microfibre fabric with UV protection and a super-soft finish. The company aims to grow to £8m by the year 2023 (with significant upside potential), £1.6m EBIT.

Pitch Rated

75%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Butterwire is a professional research and portfolio analyst platform designed for high conviction low turnover active equity managers. Butterwire's AI web application was launched in June 2018 and is used by all active equity investors aiming to generate higher returns, with faster stock selection, longer investment horizons, lower portfolio risk, and less trading. The application assists active investors with their top 3 challenges: find opportunities, minimise risk, and keep aware. It is built by and for professionals but is accessible to individual investors, too. The company will utilize 10% of the proceeds to operations, 25% to development, 15% to research, 40% to business development, and 10% to administration.
days to go: Expired investment: Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph